Enanta Pharmaceuticals (ENTA) Interest & Investment Income (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Interest & Investment Income of $2.1 million for Q1 2026, down 9.08% year-on-year from $2.3 million in Q1 2025, and down 13.96% on a QoQ basis from $2.4 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Interest & Investment Income data on file, last reported at $2.1 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 9.08% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.9 million (down 24.65% YoY), and the FY2025 full-year result was $9.4 million, down 36.07% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $2.1 million, down from $2.4 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $4.7 million in Q3 2023 and bottomed at $255000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $2.3 million (2025), against an average of $2.4 million.
- The widest annual swing landed in 2023, when Interest & Investment Income jumped 883.72%; it then sank 39.83% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $993000.0 in 2022, then jumped by 332.83% to $4.3 million in 2023, then plunged by 34.88% to $2.8 million in 2024, then slipped by 13.47% to $2.4 million in 2025, then retreated by 13.96% to $2.1 million in 2026.
- The last three Interest & Investment Income figures came in at $2.1 million (Q1 2026), $2.4 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.08 Mn |
| Dec 31, 2025 | 2.42 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 2.29 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.49 Mn |
| Mar 31, 2024 | 3.81 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 4.66 Mn |
| Jun 30, 2023 | 3.87 Mn |
| Mar 31, 2023 | 1.84 Mn |
| Dec 31, 2022 | 993,000.00 |
| Sep 30, 2022 | 631,000.00 |
| Jun 30, 2022 | 393,000.00 |
| Mar 31, 2022 | 255,000.00 |
| Dec 31, 2021 | 258,000.00 |
| Mar 31, 2020 | 1.95 Mn |
| Dec 31, 2019 | 2.08 Mn |
| Mar 31, 2019 | 2.25 Mn |
| Dec 31, 2018 | 1.89 Mn |
| Sep 30, 2018 | 1.53 Mn |
| Jun 30, 2018 | 1.33 Mn |
| Mar 31, 2018 | 1.08 Mn |
| Dec 31, 2017 | 919,000.00 |
| Sep 30, 2017 | 774,000.00 |
| Jun 30, 2017 | 617,000.00 |
| Mar 31, 2017 | 564,000.00 |
| Dec 31, 2016 | 549,000.00 |
| Sep 30, 2016 | 452,000.00 |
| Jun 30, 2016 | 474,000.00 |
| Mar 31, 2016 | 408,000.00 |
| Dec 31, 2015 | 356,000.00 |
| Sep 30, 2015 | 308,000.00 |
| Jun 30, 2015 | 304,000.00 |
| Mar 31, 2015 | 229,000.00 |
| Dec 31, 2014 | 127,000.00 |
| Sep 30, 2014 | 138,000.00 |
| Jun 30, 2014 | 106,000.00 |
| Mar 31, 2014 | 114,000.00 |
| Dec 31, 2013 | 109,000.00 |
| Sep 30, 2013 | 102,000.00 |
| Jun 30, 2013 | 64,000.00 |
| Mar 31, 2013 | 47,000.00 |
| Dec 31, 2012 | 35,000.00 |
| Sep 30, 2012 | 41,000.00 |
| Jun 30, 2012 | 48,000.00 |
| Mar 31, 2012 | 15,000.00 |